Project description
Training on precision therapeutics that target cancer-associated glycans
Glycoscience has made significant strides in the past decade. The MSCA-funded GlyCanDrug project seeks to design precision therapeutics targeting specific glycan motifs in cancer, addressing cancer heterogeneity and creating new avenues for drug discovery. The project’s goal is to train 10 doctoral candidates by assembling leading glycoscientists from 9 academic institutions and 6 SMEs. GlyCanDrug aims to suppress the expression of cancer-associated glycans and develop advanced targeting tools, leveraging scientific excellence and industry expertise throughout the entire process. The objective is to produce the next generation of glycoscientists equipped with unique skills in glycan-based therapy. The project will offer PhD students essential transferable skills, comprehensive knowledge and diverse insights into the potential of glycoscience to uncover precision therapeutics for cancer.
Objective
Glycoscience has gained such significant technological advances over the past decade, that it is now poised for giving an unprecedented contribution to high-demanding societal needs. GlyCanDrug is a glycoscience-oriented DN that aims, for the first time, to take a step ahead in the design of precision therapeutics targeting key glycan motifs implicated in cancer. These glycans are fingerprints of many cancers. Thus, their targeting has the striking potential to overcome cancer heterogeneity that limits the current targeted therapies providing new opportunities for the discovery of precision therapeutics.
The credibility and high quality of GlyCanDrug are ensured by top-level glycoscientists from 9 academic institutions (8EU & 1US) and 6 SMEs which encompass complementary and intersectoral expertise, and unique state-of-the-art technological tools to train 10 doctoral candidates (DCs). GlyCanDrug focuses on the precise inhibition of the expression of cancer-associated glycans and the development of cutting-edge tools for their targeting. The unique combination of scientific excellence in interdisciplinary fields and industry know-how will cover the entire process from obtaining fundamental insights to the implementation of innovative solutions. GlyCanDrug aims at creating a critical mass of uniquely skilled graduates in glycan-based therapies. To this aim, we will equip DCs with a thorough multifaceted knowledge of the potential of glycoscience in the discovery of cancer precision therapeutics and the necessary transferable skills. This will put DCs in an advantageous position for job opportunities in both academia and industry.
Deciphering the glycome expands the frontiers of knowledge and discovery and enables addressing fundamental challenges in cancer. Therefore, GlyCanDrug DN will strengthen the European innovation capacity by bringing new glycoscience concepts in the development of cancer precision therapeutics to market and policy stakeholders.
Fields of science
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
50121 Florence
Italy
See on map
Participants (7)
4200-135 Porto
See on map
50009 Zaragoza
See on map
2800 Kongens Lyngby
See on map
1000 Ljubljana
See on map
28006 Madrid
See on map
75794 Paris
See on map
2200 Kobehavn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (13)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
39120 Magdeburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
6229 EV Maastricht
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
51105 Koln
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1045 Budapest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
82152 Martinsried
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
33199 Miami
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1165 Kobenhavn
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1040 Bruxelles / Brussel
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
53100 Siena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4099-002 Porto
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
41004 Sevilla
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
59000 Lille
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2800 Kongens Lyngby
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.